To describe the incidence rates of visual loss and ocular complications in patients with retinal vasculitis (RV).
Retrospective cohort study METHODS: Clinical data were collected for 96 patients (175 eyes) diagnosed with RV from 2003 to 2013. Main outcome measures included rates of visual loss and ocular complications. Comparison of outcomes in patients with a relapsing versus non-relapsing disease also were analyzed.
Over a median follow-up of 44 months (range: 1-153), the rate of visual loss to 20/50 or worse was 0.13 per eye-year (/EY, 95% confidence interval [CI], 0.09/EY- 0.18/EY) and to 20/200 or worse was 0.06/EY (95% CI, 0.04/EY-0.08/EY). The most common complications were cataract (0.31/EY), epiretinal membrane (0.16/EY), and recurrent macular edema (0.09/EY). Patients with a relapsing course (median number of relapses = 1, range: 1-6) appeared to have greater risk for visual loss to 20/50 (odds ratio [OR] = 2.07; 95% CI, 0.88-4.90, p=0.09) and 20/200 or worse (OR=2.49; 95% CI, 0.98-6.30, p=0.05). Immunosuppressive drug therapy lowered the risk of visual loss, independent of relapsing disease course (OR = 0.79; 95% CI, 0.66-0.94, p=0.01 and OR= 0.73; 95% CI, 0.57-0.93, p=0.01 for the 20/50 or worse and 20/200 or worse thresholds respectively).
Rates of visual loss and complications among patients with RV were similar to reported rates in non-infectious uveitides. Treatment with immunosuppressive drugs lowered the risk of visual loss. A relapsing course suggested an increased risk for visual loss but was not statistically significant, perhaps due to low numbers of recurrences.
Pharmacology, Toxicology and Pharmaceutical Science
1
3%
Computer Science
1
3%
Neuroscience
1
3%
Other
0
0%
Unknown
10
31%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 May 2017.
All research outputs
#15,173,117
of 25,382,440 outputs
Outputs from American Journal of Ophthalmology
#3,753
of 6,478 outputs
Outputs of similar age
#170,220
of 325,190 outputs
Outputs of similar age from American Journal of Ophthalmology
#44
of 72 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,478 research outputs from this source. They receive a mean Attention Score of 4.8. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,190 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 72 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
